[Microalbuminuria and albuminuria: differential diagnosis and consequences for treatment].
The occurrence of microalbuminuria or albuminuria indicates a disturbance of the barrier function of endothelial cells, basement membrane or of a structural-renal disease (including diseased podocytes). The prevalence of microalbuminuria in the general population is about 8 %, however, in high risk groups, prevalence rates of 50 % and more have been observed. Its incidence is strongly associated with increased cardiovascular morbidity and mortality. Blood pressure control and the blockade of the renin-angiotensin-aldosteron-system (RAAS), respectively, is the central mechanism to reduce cardio-vascular-renal end points as well as mortality.
Koziolek
M J
MJ
Abteilung Nephrologie und Rheumatologie, Georg-August-Universität Göttingen. mkoziolek@med.uni-goettingen.de
Bramlage
C P
CP
Vasko
R
R
Grupp
C
C
Müller
G A
GA
D000419:Albuminuria / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D003937:Diagnosis, Differential; D005921:Glomerulonephritis / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000517:prevention & control; D015994:Incidence; D015995:Prevalence; D012084:Renin-Angiotensin System / Q000187:drug effects; D012307:Risk Factors
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors